Panel A shows absorbance at 450 nanometers for Bet v1 IgG1 where BPE reaches approximately 1.5, with CAR A2 and CAlleR 8 Treg groups showing similar levels around 1.3, all significantly higher than PBS near 0.2. Panel B shows IgE levels in micrograms per milliliter where BPE reaches approximately 0.7, declining to approximately 0.4 with CAIleR 8 Treg treatment, with significant differences marked. Panel C shows dendritic cell percent of CD11c positive CD11b positive F480 negative cells in lung ranging from approximately 35 percent in PBS to 55 percent in BPE, with CAIleR 8 Treg showing reduction. Panel D shows scatter dot plots of T cell population percentages in lung across CD3, CD4, CD8, Foxp3, and CD44 markers, with no significant differences between BPE and the CAlleR-8 condition. Panel E shows equivalent scatter dot plots for mediastinal lymph node across the same markers, where populations remain largely consistent across all four conditions with no significant differences marked.
CAlleR 8 Tregs do not prevent immunoglobulin production or the activation of T cells and DCs. (A) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA (n = 4–7 from two independent experiments). (B) Total serum IgE quantification by ELISA (n = 7–13 from two independent experiments). (C) Cumulative data on the percentage of DCs detected in the lungs (gated on CD11c+CD11b+F480−MHC-II+) (n = 4–7 from two independent experiments). (D and E) Cumulative data of the percentage of the different T populations observed in (D) the lungs and in (E) the mLN (CD3+ T cells, CD4+, CD8+, and Tregs) (n = 5–9 from two independent experiments). Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in A–C and with two-way ANOVA with Tukey’s multiple comparison test in D and E. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.